

# SEARCH REQUEST FORM

Scientific and Technical Information Center

RECEIVED

SEP 27 2002

Access DB#

76864

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 9-27-2002  
 Art Unit: 1653 Phone Number 308-3975 Serial Number: 091781133  
 Mail Box and Bldg/Room Location: CMI-9801 / CMI-9807 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Methods Of Enhancing The Bioavailability Of A Drug

Inventors (please provide full names): N. Hayward, M. Getter


Earliest Priority Filing Date: 2-9-2001

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



If there are many hits, please require R to be alkyl.

keywords are amyloid, P-glycoprotein, brain.

Thank you.  


Edward Hart  
 Technical Info. Specialist  
 STIC/Biotech  
 CMI 6B02 Tel: 305-9203

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>10/30/02</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>10/1/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>21</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>21</u>	Other _____	Other (specify) _____

=> file hcaplus  
 FILE 'HCAPLUS' ENTERED AT 14:52:23 ON 01 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 1 Oct 2002 VOL 137 ISS 14  
 FILE LAST UPDATED: 30 Sep 2002 (20020930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d stat que  
 L4

STR




NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L6 406 SEA FILE=REGISTRY SSS FUL L4  
 L9 1207 SEA FILE=REGISTRY ABB=ON PLU=ON AMYLOID/BI  
 L11 668914 SEA FILE=HCAPLUS ABB=ON PLU=ON 18  
 L12 3258 SEA FILE=HCAPLUS ABB=ON PLU=ON L9  
 L13 16312 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 OR ?AMYLOID?  
 L14 6436 SEA FILE=HCAPLUS ABB=ON PLU=ON L\*\*\* OR P (W) GLYCOPROTEIN  
 L18 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND L11 AND L14  
 L19 STR



VAR G1=ME/ET/I-PR/N-PR/I-BU/N-BU/S-BU/T-BU  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L20 6 SEA FILE=REGISTRY SUB=L6 SSS FUL L19  
 L21 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L20  
 L22 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 OR L21

=> d ibib abs hitrn l22 tot

L22 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:618207 HCAPLUS

DOCUMENT NUMBER: 135:190398

TITLE: Nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers

INVENTOR(S): Roth, Frederick P.; Van Huffel, Christophe; White, James V.; Shyjan, Andrew W.

PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001061048	A2	20010823	WO 2001-US5263	20010216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002051978	A1	20020502	US 2001-788100	20010216
PRIORITY APPLN. INFO.:			US 2000-183312P	P 20000217
AB The present invention is directed to the identification of markers that can be used to det. the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to det. the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression anal. was used to identify markers assocd. with sensitivity to certain chemotherapeutic agents.				
IT <b>117871-30-4 126236-73-5</b> , Glycophosphoprotein P (human clone pSVB1/pSVM113/pSVC6/pSVA4/pSVS13/pSVTH21 gene mdrl protein moiety reduced) <b>154947-97-4</b> RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (amino acid sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)				
IT <b>148784-57-0</b> , GenBank X68830 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (nucleotide sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)				
L22 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER: 2001:597818 HCAPLUS				
DOCUMENT NUMBER: 135:185457				
TITLE: Methods for enhancing the bioavailability of a drug				
INVENTOR(S): Hayward, Neil J.; Gefter, Malcolm L.				
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Inc., USA				
SOURCE: PCT Int. Appl., 86 pp. CODEN: PIXXD2				
DOCUMENT TYPE: Patent				
LANGUAGE: English				
FAMILY ACC. NUM. COUNT: 1				
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058470	A2	20010816	WO 2001-US4178	20010209
WO 2001058470	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-181833P P 20000211  
 US 2000-181943P P 20000211

AB The invention provides methods and compns. for enhancing the  
 bioavailability of a drug in a subject. The present invention also  
 provides methods and compns. for treating or preventing hepatic injury in  
 humans. The invention further provides methods for identifying  
 hydrophobic peptides, e.g., .beta.-amyloid peptide derivs., which are  
 useful in enhancing bioavailability of a drug. Thus, brain levels of  
 PPI-58 were elevated in the presence of cyclosporin A. The  
 biodistribution data demonstrated that higher levels were obsd. within the  
 small intestine in the presence of cyclosporin A.

IT 290828-24-9 290828-45-4  
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU  
 (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (methods for enhancing drug bioavailability)

L22 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:628174 HCAPLUS  
 DOCUMENT NUMBER: 133:221242  
 TITLE: Modulators of beta-amyloid peptide aggregation  
 comprising D-amino acids  
 INVENTOR(S): Findeis, Mark A.; Phillips, Kathryn; Olson, Gary L.;  
 Self, Christopher  
 PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052048	A1	20000908	WO 2000-US5574	20000303
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1161449	A1	20011212	EP 2000-916028	20000303
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000008738	A	20011226	BR 2000-8738	20000303
PRIORITY APPLN. INFO.:			US 1999-122736P P 19990304	
			WO 2000-US5574 W 20000303	
AB	Compds. that modulate natural .beta. amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a .beta. amyloid peptide, that is comprised entirely of D-amino			

acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a .beta. amyloid peptide, preferably a retro-inverso isomer of A.beta.17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.

IT 290828-24-9 290828-30-7 290828-31-8  
290828-45-4 290828-62-5 290828-63-6

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modulators of .beta.-amyloid peptide aggregation comprising D-amino acids)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:795994 HCAPLUS

DOCUMENT NUMBER: 132:31744

TITLE: Gene probes used for genetic profiling in healthcare screening and planning

INVENTOR(S): Roberts, Gareth Wyn

PATENT ASSIGNEE(S): Genostic Pharma Ltd., UK

SOURCE: PCT Int. Appl., 745 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964627	A2	19991216	WO 1999-GB1780	19990604
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			GB 1998-12099	A 19980606
			GB 1998-13291	A 19980620
			GB 1998-13611	A 19980624
			GB 1998-13835	A 19980627
			GB 1998-14110	A 19980701
			GB 1998-14580	A 19980707
			GB 1998-15438	A 19980716
			GB 1998-15574	A 19980718
			GB 1998-15576	A 19980718
			GB 1998-16085	A 19980724
			GB 1998-16086	A 19980724
			GB 1998-16921	A 19980805

GB 1998-17097 A 19980807  
 GB 1998-17200 A 19980808  
 GB 1998-17632 A 19980814  
 GB 1998-17943 A 19980819

AB There is considerable evidence that significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiol. response. In order to bring about the integration of genomics into medical practice and enable design and building of a technol. platform which will enable the everyday practice of mol. medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiol. states of interest. According to the invention, the no. of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide crit. clin. information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clin. prognostic information - "genostics". The "Genostic" profiling of patients and persons will radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need. The use of this invention could also lead to a host of new applications for such profiling technologies, such as identification of persons with particular work or environment related risk, selection of applicants for employment, training or specific opportunities or for the enhancing of the planning and organization of health services, education services and social services.

IT 106602-62-4, Amylin 148125-60-4  
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

IT 158736-49-3, .beta.-Secretase  
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (.alpha. and .beta. and .gamma., core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

L22 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:795993 HCAPLUS

DOCUMENT NUMBER: 132:31743

TITLE: Gene probes used for genetic profiling in healthcare screening and planning

INVENTOR(S): Roberts, Gareth Wyn

PATENT ASSIGNEE(S): Genostic Pharma Limited, UK

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9964626 A2 19991216 WO 1999-GB1779 19990604  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
AU 9941586 A1 19991230 AU 1999-41586 19990604  
AU 9941587 A1 19991230 AU 1999-41587 19990604  
GB 2339200 A1 20000119 GB 1999-12914 19990604  
GB 2339200 B2 20010912  
EP 1084273 A1 20010321 EP 1999-925207 19990604  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
PRIORITY APPLN. INFO.: GB 1998-12098 A 19980606  
GB 1998-28289 A 19981223  
GB 1998-16086 A 19980724  
GB 1998-16921 A 19980805  
GB 1998-17097 A 19980807  
GB 1998-17200 A 19980808  
GB 1998-17632 A 19980814  
GB 1998-17943 A 19980819  
WO 1999-GB1779 W 19990604  
AB There is considerable evidence that significant factor underlying the  
individual variability in response to disease, therapy and prognosis lies  
in a person's genetic make-up. There have been numerous examples relating  
that polymorphisms within a given gene can alter the functionality of the  
protein encoded by that gene thus leading to a variable physiol. response.  
In order to bring about the integration of genomics into medical practice  
and enable design and building of a technol. platform which will enable  
the everyday practice of mol. medicine a way must be invented for the DNA  
sequence data to be aligned with the identification of genes central to  
the induction, development, progression and outcome of disease or physiol.  
states of interest. According to the invention, the no. of genes and  
their configurations (mutations and polymorphisms) needed to be identified  
in order to provide crit. clin. information concerning individual  
prognosis is considerably less than the 100,000 thought to comprise the  
human genome. The identification of the identity of the core group of  
genes enables the invention of a design for genetic profiling  
technologies.  
IT 106602-62-4, Amylin 148125-60-4  
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); USES (Uses)  
(core group of disease-related genes; gene probes used for genetic  
profiling in healthcare screening and planning)  
IT 158736-49-3, .beta.-Secretase  
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); USES (Uses)  
(.alpha. and .beta. and .gamma., core group of disease-related genes;  
gene probes used for genetic profiling in healthcare screening and  
planning)

=> sel hit rn  
E1 THROUGH E13 ASSIGNED

=> file reg



FILE 'REGISTRY' ENTERED AT 14:53:28 ON 01 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9  
 DICTIONARY FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
 PROPERTIES for more information. See STNote 27, Searching Properties  
 in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s el-el3

```

1 106602-62-4/BI
  (106602-62-4/RN)
1 148125-60-4/BI
  (148125-60-4/RN)
1 158736-49-3/BI
  (158736-49-3/RN)
1 290828-24-9/BI
  (290828-24-9/RN)
1 290828-45-4/BI
  (290828-45-4/RN)
1 117871-30-4/BI
  (117871-30-4/RN)
1 126236-73-5/BI
  (126236-73-5/RN)
1 148784-57-0/BI
  (148784-57-0/RN)
1 154947-97-4/BI
  (154947-97-4/RN)
1 290828-30-7/BI
  (290828-30-7/RN)
1 290828-31-8/BI
  (290828-31-8/RN)
1 290828-62-5/BI
  (290828-62-5/RN)
1 290828-63-6/BI
  (290828-63-6/RN)
L23 13 (106602-62-4/BI OR 148125-60-4/BI OR 158736-49-3/BI OR 290828-24
      -9/BI OR 290828-45-4/BI OR 117871-30-4/BI OR 126236-73-5/BI OR
      148784-57-0/BI OR 154947-97-4/BI OR 290828-30-7/BI OR 290828-31-
      8/BI OR 290828-62-5/BI OR 290828-63-6/BI)

```


=> d ide can 123 1-13

L23 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 290828-63-6 REGISTRY  
 CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-2,3,4,5,6-

FS pentafluoro-D-phenylalanyl- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C36 H49 F5 N6 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 290828-62-5 REGISTRY  
 CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-4-fluoro-D-phenylalanyl- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C36 H53 F N6 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 290828-45-4 REGISTRY

CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-  
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3: PN: WO0158470 PAGE: 27 claimed sequence

CN PPI 1019

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C36 H54 N6 O5

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 135:185457

REFERENCE 2: 133:221242

L23 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 290828-31-8 REGISTRY  
 CN D-Leucinamide, N-propyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-  
 (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C38 H58 N6 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 290828-30-7 REGISTRY  
 CN D-Leucinamide, N-ethyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-  
 (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C37 H56 N6 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242


L23 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 290828-24-9 REGISTRY  
 CN D-Leucinamide, N,N-dimethyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-  
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN PPI 1007  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C37 H56 N6 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:185457

REFERENCE 2: 133:221242

L23 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 158736-49-3 REGISTRY  
 CN .beta.-Secretase (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .beta. Protein amyloidogenase  
 CN .beta.-Amyloid protein precursor secretase  
 CN .beta.-Site APP-cleaving enzyme  
 CN .beta.-site APP-cleaving enzyme 1  
 CN Amyloid precursor protein secretase  
 CN APP secretase  
 CN Aspartic protease BACE  
 CN Aspartic protease BACE1  
 CN D-Aspartyl-.beta.-amyloid secretase  
 CN Memapsin 2  
 CN Protease Asp2  
 CN Proteinase BACE1  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: ADISNEWS, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PROMT,  
 TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

448 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 453 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:199013  
 REFERENCE 2: 137:197417  
 REFERENCE 3: 137:194789  
 REFERENCE 4: 137:183539  
 REFERENCE 5: 137:180800  
 REFERENCE 6: 137:163820  
 REFERENCE 7: 137:163104  
 REFERENCE 8: 137:150257  
 REFERENCE 9: 137:136786  
 REFERENCE 10: 137:134242

L23 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 154947-97-4 REGISTRY

CN Proteinase, amyloid precursor protein (human clone pRc/Zyme reduced) (9CI)  
 (CA INDEX NAME)

OTHER NAMES:

CN 103: PN: WO0053776 FIG: 36 unclaimed protein  
 CN 114: PN: WO0053776 FIG: 43 unclaimed protein  
 CN 3: PN: WO0127257 SEQID: 3 unclaimed protein  
 CN 66: PN: WO0053776 SEQID: 84 unclaimed protein  
 CN GenBank AF013988-derived protein GI 2318115  
 CN GenBank AF149289-derived protein GI 5791636  
 CN GenBank AF243527-derived protein GI 11244764  
 CN GenBank U62801-derived protein GI 1518788  
 CN Kallikrein (human gene KLK6 isoenzyme hK6)  
 CN Kallikrein hK6 (human gene KLK6)  
 CN Kallikrein-like serine protease (human gene PRSS9)  
 CN Neurosin (human clone pSPORT/SP59 precursor)  
 CN Neurosin (human)  
 CN Protease M (human precursor)  
 CN Proteinase M (human gene KLK6)  
 CN Proteinase M (human precursor)  
 CN Proteinase M (human)  
 CN Proteinase, amyloid precursor protein (human clone 56Z precursor)  
 CN Proteinase, serine (human COLO 201 cell gene SP59 precursor)  
 CN Zyme (human clone 56Z precursor)  
 FS PROTEIN SEQUENCE  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
 12 REFERENCES IN FILE CA (1962 TO DATE)  
 12 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398

REFERENCE 2: 135:56769  
 REFERENCE 3: 135:29716  
 REFERENCE 4: 134:309694  
 REFERENCE 5: 133:248065  
 REFERENCE 6: 132:233371  
 REFERENCE 7: 128:241249  
 REFERENCE 8: 127:344861  
 REFERENCE 9: 127:77920  
 REFERENCE 10: 126:101081

L23 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 148784-57-0 REGISTRY  
 CN DNA (human clone .lambda.h101 islet amyloid protein IAAP cDNA plus flanks)  
 (9CI) (CA INDEX NAME)  
 FS NUCLEIC ACID SEQUENCE  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 \*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
 1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398

L23 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2002 ACS  
 RN 148125-60-4 REGISTRY  
 CN Proteinase inhibitor, protease-nexin II (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN A4751 amyloid protein precursor  
 CN Amyloid A4751 glycoproteins  
 CN Amyloid A4751 proteins  
 CN Glycoproteins, amyloid A4751  
 CN Glycoproteins, amyloid A4751  
 CN Plasminogen activator inhibitor PN 2  
 CN Protease-nexin 2  
 CN Protease-nexin II  
 CN Proteins, ABPP 751  
 CN Proteins, amyloid A4751  
 CN Proteins, amyloid precursor protein 751  
 CN Proteins, APP751  
 CN Proteins, BPP751  
 CN Proteins, protease-nexins, II  
 CN Proteins, proteinase-nexins II  
 MF Unspecified  
 CI MAN  
 SR CA

LC STN Files: BIOSIS, CA, CAPLUS, PROMT, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

102 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
102 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:121162

REFERENCE 2: 137:15809

REFERENCE 3: 136:398194

REFERENCE 4: 136:323313

REFERENCE 5: 136:132925

REFERENCE 6: 136:81953

REFERENCE 7: 136:4156

REFERENCE 8: 135:356303

REFERENCE 9: 135:342469

REFERENCE 10: 135:314399

L23 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 126236-73-5 REGISTRY

CN Glycophosphoprotein P (human clone pSVB1/pSVM113/pSVC6/pSVA4/pSVS13/pSVTH2  
1 gene mdrl protein moiety reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO0121762 SEQID: 1 unclaimed protein

CN 24: PN: WO0192877 SEQID: 2 unclaimed protein

CN 2: PN: WO9961589 SEQID: 2 unclaimed protein

CN GenBank M29447-derived protein GI 386862

CN P glycoprotein (human gene MDRL)

CN P glycoprotein (human)

FS PROTEIN SEQUENCE

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

6 REFERENCES IN FILE CA (1962 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:34297

REFERENCE 2: 135:193985

REFERENCE 3: 135:190398

REFERENCE 4: 134:247227

REFERENCE 5: 132:9605



REFERENCE 6: 112:152804

L23 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 117871-30-4 REGISTRY

CN Amylin, prepro- (human clone .lambda.hIAP-1 reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 12: PN: WO9956763 SEQID: 12 unclaimed protein

CN 2: PN: US6110707 SEQID: 53 claimed protein

CN Amylin, prepro- (human clone .lambda.h201 reduced)

CN GenBank X68830-derived protein GI 32583

CN Islet amyloid polypeptide IAAP (human clone .lambda.h101 )

FS PROTEIN SEQUENCE

DR 125199-66-8

MF C436 H717 N125 O125 S3

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

10 REFERENCES IN FILE CA (1962 TO DATE)

10 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398

REFERENCE 2: 133:206891

REFERENCE 3: 131:350243

REFERENCE 4: 127:186606

REFERENCE 5: 118:183631

REFERENCE 6: 113:146480

REFERENCE 7: 112:230555

REFERENCE 8: 112:173362

REFERENCE 9: 111:209451

REFERENCE 10: 110:226301

L23 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 106602-62-4 REGISTRY

CN Amylin (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Diabetes-associated peptide

CN Insulinoma amyloid peptide

CN Insulinoma amyloid polypeptide

CN Islet amyloid polypeptide

MF Unspecified

CI COM, MAN

SR CA

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CIN, EMBASE, MEDLINE, MRCK\*, PROMT, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

880 REFERENCES IN FILE CA (1962 TO DATE)

33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

882 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:200265

REFERENCE 2: 137:190764

REFERENCE 3: 137:183587

REFERENCE 4: 137:179976

REFERENCE 5: 137:174934

REFERENCE 6: 137:174933

REFERENCE 7: 137:174932

REFERENCE 8: 137:174931

REFERENCE 9: 137:159362

REFERENCE 10: 137:150247